Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sepetaprost vs Latanoprost in POAG/OHT (Angel-J1)
NCT05495061Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Aug 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of sepetaprost in primary open-angle glaucoma (POAG) and ocular hypertension (2 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Change from baseline in mean diurnal intraocular pressure at 4 weeks. Started Aug 2022; status: completed.
02
Drugs
sepetaprost
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT05495061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05495061.